NovaBay Pharmaceuticals, Inc. 8-K

What Happened

• NovaBay Pharmaceuticals, Inc. filed an 8-K (Item 5.03) reporting a 1-for-5 reverse stock split of its common stock that became effective at 4:15 p.m. Eastern Time on February 20, 2026. The company filed a Certificate of Amendment to its Certificate of Incorporation to effect the change.

Key Details

• Reverse split ratio: 1-for-5; every 5 issued and outstanding shares were combined into 1 share.
• Effective time/date: Certificate of Amendment effective at 4:15 p.m. ET on February 20, 2026; NYSE American trading will reflect the split at market open on February 23, 2026.
• Trading symbol/CUSIP: Symbol remains "NBY"; new CUSIP is 66987P 508.
• Share mechanics and authorization: No fractional shares were issued—holders who would have received fractions were issued an additional whole share; par value per share and total authorized common shares (1,500,000,000) remain unchanged.

Why It Matters

• The reverse split consolidates the company’s outstanding shares and will proportionally increase the per‑share trading price while leaving each stockholder’s percentage ownership unchanged (except for minor rounding due to fractional‑share treatment).
• Investors should note the adjusted trading date, new CUSIP, and that the split does not change the company’s authorized share count or the par value of common stock.